Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours

BACKGROUND: Sapanisertib (TAK-228) is an investigational, orally available, potent and highly selective mTORC1/2 inhibitor demonstrating promise in numerous malignancies. This phase I study (NCT02412722) evaluated the safety, tolerability, pharmacokinetics and antitumour activity of single-agent TAK...

Descripción completa

Detalles Bibliográficos
Autores principales: Moore, Kathleen N, Bauer, Todd M, Falchook, Gerald S, Chowdhury, Swapan, Patel, Chirag, Neuwirth, Rachel, Enke, Aaron, Zohren, Fabian, Patel, Manish R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812400/
https://www.ncbi.nlm.nih.gov/pubmed/29464110
http://dx.doi.org/10.1136/esmoopen-2017-000291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812400/
https://www.ncbi.nlm.nih.gov/pubmed/29464110
http://dx.doi.org/10.1136/esmoopen-2017-000291

Ejemplares similares